Cargando…

Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved rapidly, leading to viral lineages characterized by multiple mutations in the spike protein, which could potentially confer to the virus the ability to avoid the vaccine-induced immune response, making the vaccines less effecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valleriani, Fabrizia, Mancuso, Elisa, Vincifori, Giacomo, Teodori, Liana, Di Marcantonio, Lisa, Spedicato, Massimo, Leone, Alessandra, Savini, Giovanni, Morelli, Daniela, Bonfini, Barbara, Lorusso, Alessio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540752/ https://www.ncbi.nlm.nih.gov/pubmed/34696441 http://dx.doi.org/10.3390/v13102011

Ejemplares similares

Intravenous Infection of Small Ruminants Suggests a Goat-Restricted Host Tropism and Weak Humoral Immune Response for an Atypical Bluetongue Virus Isolate
por: Spedicato, Massimo, et al.
Publicado: (2023)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
por: Favresse, Julien, et al.
Publicado: (2021)

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Canti, Lorenzo, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

A Deletion Encompassing the Furin Cleavage Site in the Spike Encoding Gene Does Not Alter SARS-CoV-2 Replication in Lung Tissues of Mink and Neutralization by Convalescent Human Serum Samples
por: Valleriani, Fabrizia, et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Saraceni, Francesco, et al.
Publicado: (2021)

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021)

Evaluation of neutralizing antibodies after vaccine BNT162b2: Preliminary data
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients
por: Fu, Jia, et al.
Publicado: (2022)

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2023)

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
por: Peled, Yael, et al.
Publicado: (2021)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
por: Bates, Timothy A., et al.
Publicado: (2021)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

BNT162b2 induced neutralizing and non-neutralizing antibody functions against SARSCoV-2 diminish with age
por: Bates, Timothy A., et al.
Publicado: (2022)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

The SARS-CoV-2–neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccine
por: Pedersen, Rune M., et al.
Publicado: (2021)

(6) BNT162b2-Vaccine-Induced Neutralization Responses are Immune Correlates of Clinical Protection Against SARS-CoV-2 in Heart Transplant Recipients
por: Peled, Y., et al.
Publicado: (2023)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age
por: Bates, Timothy A., et al.
Publicado: (2022)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
por: Baek, Yae Jee, et al.
Publicado: (2023)

Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population()
por: Kawasuji, Hitoshi, et al.
Publicado: (2022)

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

Long-Term Neutralizing Antibody Titers After BNT162b2 Vaccination in Hemodialysis Patients
por: Takazono, Takahiro, et al.
Publicado: (2023)

Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients
por: Higashimoto, Yuki, et al.
Publicado: (2022)

Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
por: Costard-Jäckle, Angelika, et al.
Publicado: (2022)

Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, following Vaccination with BNT162b2
por: Fylaktou, Asimina, et al.
Publicado: (2023)

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
por: Wang, Bei, et al.
Publicado: (2021)

Limited Neutralization of Omicron by Antibodies from the BNT162b2 Vaccination against SARS-CoV-2
por: Lanz, Tobias V., et al.
Publicado: (2022)

BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients
por: Hod, Tammy, et al.
Publicado: (2022)

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2022)

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors
por: Tan, Chee-Wah, et al.
Publicado: (2021)

Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2
por: Speer, Claudius, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i12rokl1c1k3e7i2nt6rm022hn